Advice

in the absence of a submission from the holder of the marketing authorisation

cannabinoid oromucosal spray (Sativex®) is not recommended for use within NHS Scotland.

Indication under review: as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice68KB (PDF)

Download

Medicine details

Medicine name:
cannabinoid (Sativex)
SMC ID:
703/11
Indication:
as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
Pharmaceutical company
Bayer plc/Bayer Schering Pharma
BNF chapter
Musculoskeletal and joint diseases
Submission type
Non submission
Status
Not recommended
Date advice published:
11 April 2011